Localization of sentinel lymph node in breast cancer. A prospective study

Salvatore Buscemi, Attilio Ignazio Lo Monte, Giuseppe Buscemi, Giuseppe Damiano, Vincenzo Davide Palumbo, Antonio Marrazzo, Vincenzo Davide Palumbo, Pietra Taormina, Antonio Marrazzo, Emilia Marrazzo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Sentinel Lymph Node Biopsy (SLNB) is the standard of care for staging axillary lymph nodesin women with breast cancer and clinically negative nodes. It is associated with reduced arm morbidity,moderated or severe lymphoedema, and a better quality of life in comparison with standard axillarytreatment. Unfortunately, skip metastases makes all minimally invasive approaches, such as axillarysampling, unreliable. The aim of the present clinical prospective study is to evaluate the position of SLNin an important number of cases and establish the real incidence of skip metastases in clinically nodenegativepatients.Patients and methods: A cohort of 898 female patients with breast carcinoma was considered, from 2001to 2008. Once SLN was localized, by means of radio-colloid or blue dye staining, and isolated, a biopsywas performed. Only those positive for metastases were submitted to axillary dissection.Results: Only in nine cases a SLN was not isolated. We had 819 cases of first level SLN (group A) and 69cases of second level SLN (group B). Considering all of 889 cases, SLN was localized in the second level in69 patients (7.8%); but if we consider metastatic SLN alone (340 cases), it was in the second level in 23subjects (6.8%). In total, we had a positive second level SLN in 2.3% of cases (23/889).Conclusion: Second level SLN could be considered only an anomalous lymphatic axillary drainage and itdoes not linked to particular histological variants of the primitive tumour. In our study, skip metastaseswere recognized in only 2.6% of cases, therefore, whenever a SLN is not isolated for any reason, the firstlevel sampling represent a viable operative choice.
Original languageEnglish
Pages (from-to)S162-S164
Number of pages3
JournalInternational Journal of Surgery
Volume12
Publication statusPublished - 2014

Fingerprint

Prospective Studies
Breast Neoplasms
Neoplasm Metastasis
Sentinel Lymph Node Biopsy
Lymphedema
Colloids
Lymph
Standard of Care
Radio
Dissection
Drainage
Coloring Agents
Quality of Life
Staining and Labeling
Morbidity
Incidence
Sentinel Lymph Node
Neoplasms
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Localization of sentinel lymph node in breast cancer. A prospective study. / Buscemi, Salvatore; Lo Monte, Attilio Ignazio; Buscemi, Giuseppe; Damiano, Giuseppe; Palumbo, Vincenzo Davide; Marrazzo, Antonio; Palumbo, Vincenzo Davide; Taormina, Pietra; Marrazzo, Antonio; Marrazzo, Emilia.

In: International Journal of Surgery, Vol. 12, 2014, p. S162-S164.

Research output: Contribution to journalArticle

@article{ca571fcd085b47a38691545c2654ba06,
title = "Localization of sentinel lymph node in breast cancer. A prospective study",
abstract = "Introduction: Sentinel Lymph Node Biopsy (SLNB) is the standard of care for staging axillary lymph nodesin women with breast cancer and clinically negative nodes. It is associated with reduced arm morbidity,moderated or severe lymphoedema, and a better quality of life in comparison with standard axillarytreatment. Unfortunately, skip metastases makes all minimally invasive approaches, such as axillarysampling, unreliable. The aim of the present clinical prospective study is to evaluate the position of SLNin an important number of cases and establish the real incidence of skip metastases in clinically nodenegativepatients.Patients and methods: A cohort of 898 female patients with breast carcinoma was considered, from 2001to 2008. Once SLN was localized, by means of radio-colloid or blue dye staining, and isolated, a biopsywas performed. Only those positive for metastases were submitted to axillary dissection.Results: Only in nine cases a SLN was not isolated. We had 819 cases of first level SLN (group A) and 69cases of second level SLN (group B). Considering all of 889 cases, SLN was localized in the second level in69 patients (7.8{\%}); but if we consider metastatic SLN alone (340 cases), it was in the second level in 23subjects (6.8{\%}). In total, we had a positive second level SLN in 2.3{\%} of cases (23/889).Conclusion: Second level SLN could be considered only an anomalous lymphatic axillary drainage and itdoes not linked to particular histological variants of the primitive tumour. In our study, skip metastaseswere recognized in only 2.6{\%} of cases, therefore, whenever a SLN is not isolated for any reason, the firstlevel sampling represent a viable operative choice.",
author = "Salvatore Buscemi and {Lo Monte}, {Attilio Ignazio} and Giuseppe Buscemi and Giuseppe Damiano and Palumbo, {Vincenzo Davide} and Antonio Marrazzo and Palumbo, {Vincenzo Davide} and Pietra Taormina and Antonio Marrazzo and Emilia Marrazzo",
year = "2014",
language = "English",
volume = "12",
pages = "S162--S164",
journal = "International Journal of Surgery",
issn = "1743-9191",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Localization of sentinel lymph node in breast cancer. A prospective study

AU - Buscemi, Salvatore

AU - Lo Monte, Attilio Ignazio

AU - Buscemi, Giuseppe

AU - Damiano, Giuseppe

AU - Palumbo, Vincenzo Davide

AU - Marrazzo, Antonio

AU - Palumbo, Vincenzo Davide

AU - Taormina, Pietra

AU - Marrazzo, Antonio

AU - Marrazzo, Emilia

PY - 2014

Y1 - 2014

N2 - Introduction: Sentinel Lymph Node Biopsy (SLNB) is the standard of care for staging axillary lymph nodesin women with breast cancer and clinically negative nodes. It is associated with reduced arm morbidity,moderated or severe lymphoedema, and a better quality of life in comparison with standard axillarytreatment. Unfortunately, skip metastases makes all minimally invasive approaches, such as axillarysampling, unreliable. The aim of the present clinical prospective study is to evaluate the position of SLNin an important number of cases and establish the real incidence of skip metastases in clinically nodenegativepatients.Patients and methods: A cohort of 898 female patients with breast carcinoma was considered, from 2001to 2008. Once SLN was localized, by means of radio-colloid or blue dye staining, and isolated, a biopsywas performed. Only those positive for metastases were submitted to axillary dissection.Results: Only in nine cases a SLN was not isolated. We had 819 cases of first level SLN (group A) and 69cases of second level SLN (group B). Considering all of 889 cases, SLN was localized in the second level in69 patients (7.8%); but if we consider metastatic SLN alone (340 cases), it was in the second level in 23subjects (6.8%). In total, we had a positive second level SLN in 2.3% of cases (23/889).Conclusion: Second level SLN could be considered only an anomalous lymphatic axillary drainage and itdoes not linked to particular histological variants of the primitive tumour. In our study, skip metastaseswere recognized in only 2.6% of cases, therefore, whenever a SLN is not isolated for any reason, the firstlevel sampling represent a viable operative choice.

AB - Introduction: Sentinel Lymph Node Biopsy (SLNB) is the standard of care for staging axillary lymph nodesin women with breast cancer and clinically negative nodes. It is associated with reduced arm morbidity,moderated or severe lymphoedema, and a better quality of life in comparison with standard axillarytreatment. Unfortunately, skip metastases makes all minimally invasive approaches, such as axillarysampling, unreliable. The aim of the present clinical prospective study is to evaluate the position of SLNin an important number of cases and establish the real incidence of skip metastases in clinically nodenegativepatients.Patients and methods: A cohort of 898 female patients with breast carcinoma was considered, from 2001to 2008. Once SLN was localized, by means of radio-colloid or blue dye staining, and isolated, a biopsywas performed. Only those positive for metastases were submitted to axillary dissection.Results: Only in nine cases a SLN was not isolated. We had 819 cases of first level SLN (group A) and 69cases of second level SLN (group B). Considering all of 889 cases, SLN was localized in the second level in69 patients (7.8%); but if we consider metastatic SLN alone (340 cases), it was in the second level in 23subjects (6.8%). In total, we had a positive second level SLN in 2.3% of cases (23/889).Conclusion: Second level SLN could be considered only an anomalous lymphatic axillary drainage and itdoes not linked to particular histological variants of the primitive tumour. In our study, skip metastaseswere recognized in only 2.6% of cases, therefore, whenever a SLN is not isolated for any reason, the firstlevel sampling represent a viable operative choice.

UR - http://hdl.handle.net/10447/95597

M3 - Article

VL - 12

SP - S162-S164

JO - International Journal of Surgery

JF - International Journal of Surgery

SN - 1743-9191

ER -